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ABSTRACT 1 
The Epstein-Barr virus (EBV) uses nasopharyngeal-associated lymphoid tissue (NALT) as portal 2 
of entry to establish life-long persistence in memory B-cells. We previously showed that naïve 3 
and memory B-cells from NALT are equally susceptible to EBV infection. Here, we show that 4 
memory B-cells from NALT are significantly more susceptible to EBV infection than those from 5 
remote lymphatic organs. We identify β1 integrin, which is expressed highest by naïve B-cells of 6 
distinct lymphoid origin and by memory B-cells from NALT, as mediator of increased 7 
susceptibility to infection by EBV. Furthermore, we show that BMRF-2-β1 integrin interaction 8 
and the downstream signal transduction pathway is critical for post-binding events. Increase of β1 9 
integrin expression in peripheral blood memory B-cells provoked by CD40 stimulation plus B-10 
cell receptor cross-linking increased the susceptibility of non-NALT memory B-cells to EBV 11 
infection. Thus, EBV seems to utilize the increased activation status of memory B-cells residing 12 
in the NALT to establish and ensure persistence.  13 
 at Universitaet Zuerich on M
ay 3, 2010 
jvi.asm.org
D
ow
nloaded from
 
JVI02675-09 Version 2 
 3 
INTRODUCTION 1 
The Epstein-Barr virus (EBV) is a ubiquitous human γ-herpesvirus that is transmitted via saliva 2 
and infects more than 90% of the world’s population (21). Much of EBV’s medical importance 3 
relates to its association with B-cell malignancies including Burkitt’s lymphoma, Hodgkin’s 4 
lymphoma, and post-transplant lymphoproliferative disease (21). The oncogenic potential of 5 
EBV is clearly illustrated by its unique capability to growth-transform B-cells in vitro (21). 6 
In the current paradigm, EBV infects naïve B-cells in vivo in tonsils (32). EBV is mainly 7 
present as a latent virus; upon infection EBV expresses distinct patterns of its latency genes 8 
depending upon distinct B-cell differentiation stages, varying from expression of all 10 known 9 
EBV latent genes in naïve B-cells to complete absence of EBV mRNA expression in resting 10 
memory B-cells. This has led to the model that EBV, by virtue of expression of its latency genes, 11 
provides cell survival signals in naïve B-cells (32). Recent data suggested that EBV, in particular, 12 
expedites the antigen-driven somatic hypermutation and selection process of B-cells taking place 13 
in germinal centers (GC) (26). Chaganti et al. challenge the current paradigm showing in patients 14 
with primary EBV infection that EBV avoids GC transit and infects directly memory B-cells (6). 15 
This report is consistent with in vitro experiments showing that EBV is able to infect memory B-16 
cells (9, 10) besides the well accepted susceptibility of naïve and GC B-cells to EBV. 17 
Irrespective of what B-cell subset is the primary target of EBV, it’s propagation within the 18 
host is linked to proliferation of infected B-cells which delivers latent EBV to daughter cells or, 19 
more rarely, to switching of EBV to lytic infection (21). This latter process can eventually be 20 
triggered by the differentiation of infected memory B-cells to plasma cells, and results in the 21 
release of virions that may subsequently infect new B-cells (17). Importantly, transmission of 22 
EBV to naïve hosts is thought to occur via droplets loaded with virions (21). Thus, lytic 23 
replication of EBV best takes place in nasopharyngeal-associated lymphoid tissue (NALT) which 24 
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will release EBV into the saliva, generating infectious droplets. Therefore, the NALT is the 1 
neuralgic point of EBV transmission, i.e., as portal of entry of EBV as well as shedding organ for 2 
further transmission (21).  3 
The attachment of EBV to B-cells is mediated by the direct interaction of EBV 4 
glycoprotein gp350/220 with cellular CD21, initiating receptor-mediated endocytosis. After 5 
binding to CD21, EBV gp42 can interact with host HLA class II, leading to a conformational 6 
change in the viral glycoproteins and triggering fusion with the host cell membrane (12, 28). 7 
Nevertheless, experimental data suggests that CD21 and HLA class II are dispensable for the 8 
infection of B-cells (14). Notably, in polarized oropharyngeal epithelial cells which lack CD21, 9 
interactions between the EBV glycoprotein BMRF-2 via its Arg-Gly-Asp (RGD) motif with β1 10 
integrin is critical for infection (34, 38, 39). The role of β1 integrin in mediating EBV infection of 11 
memory B-cells from NALT or non-NALT is unknown. 12 
We have recently demonstrated that tonsillar memory B-cells are much more susceptible 13 
to EBV infection than those from the peripheral blood, originating from various lymphoid tissues 14 
(9). Thus, tonsillar memory B-cells seem to express properties which render them more 15 
susceptible to EBV infection compared to their counterparts from other lymphatic origin. 16 
Here, we hypothesized that memory B-cells from the NALT exhibit specific properties 17 
rendering them highly susceptible for EBV infection. Indeed, in this work, we found that memory 18 
B-cells from the NALT are distinguished from memory B-cells of other lymphoid tissue by their 19 
β1 integrin expression levels and thus their activation status and that this higher expression level 20 
is a critical factor for their higher susceptibility to EBV infection. 21 
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MATERIALS AND METHODS 1 
Cell culture and viruses. Cells were maintained in RPMI1640 supplemented with 10% FBS, 1% 2 
L-glutamine and 1% penicillin/streptomycin (all from Gibco, Basel, Switzerland). The EBV 3 
strains used were B95.8, B95.8EBfaV-GFP carrying a CMV-EGFP cassette (29, 30) (kindly 4 
provided by Richard Longnecker, Northwestern University Feinberg School of Medicine, 5 
Chicago, Illinois), and B27 expressing low BMRF-2 levels (38). B95.8EBfaV-GFP and B27 were 6 
constantly cultivated in the presence of G-418 (Sigma, Buchs, Switzerland) to maximize the yield 7 
of recombinant virus. Flow cytometry analysis after staining for EBER (8) showed that among 8 
the recombinant EBV producer cells (B95.8EBfaV-GFP and B27) less than 2 % were positive for 9 
EBER but did not express grenn fluorescence protein (GFP). Virus production was performed as 10 
described previously (9). The same virus stocks were used for all experiments in order to exclude 11 
bias from batch-dependent viral titers, except where indicated. Inactivation of EBV was 12 
performed either by heat-inactivation at 56°C or 95°C for 60 min. 13 
 14 
DNAse treatment. To remove non-encapsidated EBV DNA before EBV DNA quantification, 15 
viral stocks were treated with DNAse according to the instructions of the manufacturer (Ambion, 16 
Austin, TX). 17 
 18 
Quantitative PCR (qPCR) assay. Quantification of EBV DNA copies in viral stocks was 19 
carried out after DNAse treatment using the TaqMan (Applied Biosystems, Rotkreuz, 20 
Switzerland) real-time PCR technique with a PCR primer-probe-system targeting the conserved 21 
EBV BamHI W region as reported (3). Serial dilutions of EBV DNA calibrated to an EBV-22 
specific plasmid were included in every PCR run (3).  23 
 24 
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EBER in situ hybridization. The presence of EBER in single cells was checked for by in situ 1 
hybridization and flow cytometry as reported (8), with the modification that the EBER 2 
hybridization probe was linked to Atto620 (Microsynth, Balgach, Switzerland). EBV-negative 3 
Ramos Burkitt lymphoma cells and lymphoblastoid cell line (LCL) cells were used as negative 4 
and positive controls, respectively. 5 
 6 
Antibodies and reagents. Antibodies to CD19, CD20, CD27, CD29, or CD62L were from BD 7 
Biosciences (Allschwil, Switzerland). Blocking antibodies against α5β1 integrin and EBV 8 
gp350/220 were from Abcam (Cambridge, United Kingdom), the EBV gp42 (clone F2.1) 9 
blocking antibody was kindly provided by Dr. L. Hutt-Fletcher (Louisiana State University, 10 
Shreveport, Louisiana), recombinant β1 integrin was from Thermo Scientific (Surrey, United 11 
Kingdom) and blocking antibodies against CD21 or HLA-DR,DP,DQ from Biolegend (Luzern, 12 
Switzerland). The inhibitors PP2, Wortmannin, Cytochalasin D and AG-82 were from 13 
Calbiochem (Dietikon, Switzerland) and Ly-294002 from Sigma-Aldrich. Antibodies detecting 14 
pY397 FAK or FAK were from BD Biosciences. Antibodies detecting pY416 c-Src, c-Src, 15 
pY458 pI3K p85α, PI3K p85α, pS3 cofilin, cofilin and all HRP-conjugated secondary antibodies 16 
were from Cell Signaling (Allschwil, Switzerland). Anti-human IgM and CD40L were from 17 
R&D Systems (Abingdon, United Kingdom). Cells were stimulated with concentrations 18 
recommended by the manufacturer. 19 
 20 
Isolation of cells. Human mononuclear cells were isolated from tonsils of donors undergoing 21 
routine tonsillectomy, from peripheral blood, and from mesenteric lymph nodes of donors 22 
undergoing abdominal surgery. Donors were EBV-seronegative. Tonsillar and mesenteric lymph 23 
node mononuclear cells were prepared as previously described (9). B-cell subsets separation was 24 
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performed by using the B-cell isolation kit II and CD27 microbeads according to the 1 
manufacturer’s instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). The purity of the 2 
isolated subsets was determined by flow cytometry and was above 90% in all preparations. This 3 
study was conducted according to the principles expressed in the Declaration of Helsinki. The 4 
study was approved by the Institutional Review Board of the University Children’s Hospital of 5 
Zurich (IRB study # StV 29/06) and University Hospital of Zurich (IRB study # EK 607). All 6 
subjects provided written informed consent for the collection of samples and subsequent analysis. 7 
 8 
Infection of cells. EBV infection was performed as described earlier (9) with minor 9 
modifications. Briefly, supernatants of B95.8, B95.8EBfaV-GFP, or B27 BMRF-2low cells were 10 
centrifuged at 40.000xg for 2 h at 4°C. The pellet was resuspended in PBS and 10% of high-titer 11 
EBV (0.5-2.5 x 108 EBV DNA copies/ml after DNAse treatment) was added to the memory B-12 
cells. The cells were then subjected to spinoculation at 4°C at 800g for 60 min as conventional 13 
inoculation with EBV-containing supernatants normally does not yield sufficient numbers of 14 
infected cells to permit detailed susceptibility studies (9). All infection frequencies shown using 15 
B95.8EBfaV-GFP were quantified using flow cytometry 24 h post inoculation of cells.  16 
 17 
EBV binding assay. Isolated B-cells or monocytes from peripheral blood were incubated with 18 
either wild-type B95.8 or B27 BMRF-2low EBV at either multiplicity of infection (moi) 5 or 25 19 
per cell for 2 h at 4°C. Following extensive washing of the cells with ice-cold PBS, RNA was 20 
extracted and the number of bound EBV DNA copies was determined by qPCR as previously 21 
described (38). 22 
 23 
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Inhibition of EBV infection. Inhibition of EBV receptors was performed by incubating memory 1 
B-cells with either anti-human CD21 (1:100), anti-human HLA-DR,DP,DQ (1:10), dilutions of 2 
anti-human CD20, or dilutions of anti-β1 integrin for 1 h at 4°C followed by spinoculation of the 3 
cells. Inhibition of EBV glycoproteins was performed by incubation of the EBV-containing 4 
supernatants with either anti-gp350/220 (1:100), or dilutions of anti-gp42 or soluble recombinant 5 
β1 integrin for 1 h at 4°C prior to spinoculation of memory B-cells. Inhibition of the integrin 6 
signaling was performed by incubating the cells with either PP2 (10µM), wortmannin (10nM), 7 
Ly-294002 (10µM), AG-82 (10µM) or cytochalasin D (10µM) for 30 min prior to spinoculation 8 
with EBV. 9 
 10 
Western blotting. Cells were resuspended in 200µl modified RIPA buffer. Total amounts of 11 
protein in each sample were quantified and normalized using Nanodrop technology (Willington, 12 
DE) and samples were separated on a 4-12% Bis-Tris NuPAGE gel (Invitrogen, Carlsbad, 13 
California).  14 
 15 
Fluorescence microscopy. Cells were washed with ice-cold PBS and were cytospun on 16 
microscopy slides. Fixation was performed in 4% paraformaldehyde for 20 min prior to 17 
permeabilization for 3 min using 0.1% TritonX-100. Actin was stained using FITC-Phalloidin 18 
(Sigma-Aldrich) for 1 h at room temperature. 19 
 20 
Flow cytometry and fluorescence-activated cell sorting. Flow cytometry was performed using 21 
a Cytomics FC 500 (Beckman Coulter, Nyon, Switzerland) and fluorescence-activated cell 22 
sorting was done using a MoFlo (Dako Cytomation, Glostrup, Denmark) 23 
 24 
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DNA microarrays. RNA from isolated tonsillar or peripheral blood B-cells was extracted using 1 
the TRIzol method (Invitrogen). Quality was verified on a 2100 Bioanalyzer and Nanodrop. RNA 2 
was transcribed to cRNA using the NuGEN System. The synthesized cRNA was hybridized to 3 
U133Plus2.0 GeneChips (Affymetrix) and scanned using an Affymetrix GeneChip Scanner 3000 4 
per Affymetrix protocols. Results were analyzed using Genespring 9 software (Agilent). 5 
 6 
Statistics. Statistical analyses were performed using Graphpad Prism Software (La Jolla, CA). 7 
Dual comparisons were analyzed using a two-tailed Mann-Whitney t-test. P values below 0.05 8 
were considered as being statistically significant. 9 
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RESULTS 1 
Susceptibility of memory B-cells from various lymphoid tissues to EBV infection. 2 
.Even though peripheral blood resting memory B-cells are the main reservoir for EBV persistence 3 
in vivo (26), memory B-cells from peripheral blood appear to be less susceptible to EBV 4 
infection in vitro than their tonsillar counterparts (1, 9). This may indicate that EBV 5 
preferentially infects memory B-cells from the NALT rather than from other lymphoid tissues. 6 
To investigate tissue-specific EBV infection susceptibility in detail, we performed infection 7 
assays of lymphoid cells from tonsils, peripheral blood, and mesenteric lymph nodes by 8 
spinoculation of the EBV strain B95.8EBfaV-GFP to quantify the EBV-infected memory B-cells 9 
by flow cytometry as previously described (9). Notably, following spinoculation EBV enters B-10 
cells by the well known EBV receptors, i.e., CD21 and HLA-DR (9). Memory B-cells were 11 
identified by expression of CD19 and CD27 (31). 12 
Memory B-cells from tonsils, which are part of the Waldeyer’s ring forming the NALT, 13 
showed the highest susceptibility to EBV infection with 83.1 ± 9.1 % of infected cells 24 hours 14 
post inoculation (Fig. 1A). In contrast, memory B-cells from peripheral blood which represent a 15 
mixture of memory B-cells from all lymphatic compartments exhibited lower infection 16 
frequencies of 30.3 ± 13.6 % (p = 0.002) and memory B-cells from mesenteric lymph nodes 17 
exhibited even lower infection frequencies of 6.7.0 ± 3.1 % (p = 0.02). This suggested that EBV 18 
preferentially infects memory B-cells originating from NALT (Fig. 1A). 19 
As the expression of L-selectin (CD62L) on memory B-cells is strongly associated with 20 
NALT origin (5) we used this cell surface marker to further characterize the origin of EBV-21 
infected memory B-cells from the various lymphoid tissues. Tonsils, where NALT-originating 22 
memory B-cells are generated, contained 81.6 ± 6.7 % CD19+CD27+ memory B-cells expressing 23 
CD62L indicating that less than 20 % of the memory B-cells have homed to the tonsil from 24 
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remote lymphatic organs (Fig. 1B). In contrast only 21.5 ± 6.9 % (p = 0.002) and 16.0 ± 5.3 % (p 1 
= 0.01) of the CD19+CD27+ peripheral blood and mesenteric lymph node memory B-cells, 2 
respectively, expressed CD62L (Fig. 1B), documenting that only a minority of the memory B-3 
cells in these lymphoid tissues expresses the NALT-associated cell surface marker. 4 
CD19+CD27+CD62L+ memory B-cells isolated from tonsils, peripheral blood, or lymph 5 
nodes showed higher EBV infection susceptibility frequencies (75.8 ± 5.0 %, 67.8 ± 7.9 %, and 6 
68.0 ± 9.2 %, respectively) than their CD19+CD27+CD62L- counterparts (40.0 ± 7.0 %, 16.0 ± 7 
4.7 %, and 14.2 ± 3.1 %, respectively; Fig. 1C). Importantly, neither exposure to nor infection 8 
with EBV in vitro did alter the levels of CD62L expression on memory B-cells (data not shown). 9 
Thus, the presence of CD62L on the cell surface was associated with a significantly higher 10 
susceptibility to EBV infection compared with the absence of CD62L. 11 
To investigate whether CD62L might be a cellular receptor for EBV in addition to the 12 
identified EBV receptors on B-cells, i.e. CD21 and HLA class II, we performed EBV infection 13 
experiments using tonsillar memory B-cells and CD62L blocking antibodies. We could not 14 
observe any inhibition of EBV infection by CD62L-blocking antibodies, even at very high 15 
antibody concentrations (Fig. 1D). Thus, CD62L defines a subset of NALT-originating memory 16 
B-cells that is phenotypically characterized by increased susceptibility to EBV infection but 17 
appears not to be involved in the cell infection process. 18 
 19 
Expression of α5β1 integrin on memory B-cells from various lymphoid tissues. Next, we were 20 
interested in identifying among cell surface structures potential candidates contributing to 21 
preferential infection of memory B-cells from NALT compared to those of other secondary 22 
lymphoid tissues. EBV is able to infect epithelial cells despite their lack of CD21, the main 23 
receptor for EBV on B-cells. Thus, we hypothesized that epithelial cell surface structures 24 
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facilitating or mediating EBV entry are present and active on memory B-cells. Recently, it has 1 
been described that the integrin receptor family, including the α5β1 integrin, plays an important 2 
role in EBV attachment to epithelial cells (38, 39). This process is mediated by the EBV 3 
glycoprotein BMRF-2 (39). 4 
To identify whether the differential susceptibility of memory B-cells from NALT and 5 
non-NALT might be due to dissimilar α5β1 integrin expression levels, we measured the 6 
expression profile of integrins in B-cells from tonsils and peripheral blood, respectively. Here, 7 
especially the integrin subunits α5 and β1 and the integrin-related genes TIF6 and PTK2 were 8 
found to be significantly up-regulated in tonsillar B-cells (Fig. 2A), indicating that signaling via 9 
α5β1 integrin is particularly important in B-cells originating from the tonsils. To confirm these 10 
data at the protein level, we isolated memory B-cells from tonsils, peripheral blood and 11 
mesenteric lymph nodes and subjected them to immunofluorescent staining for α5β1 integrin and 12 
flow cytometry. Immunofluorescence showed a weaker expression of α5β1 integrin on memory 13 
B-cells from peripheral blood compared to tonsils even though all cells expressed at least low 14 
levels of α5β1 integrin (Fig. 2B and 2C). This observation was further validated by quantification 15 
of the α5β1 integrin expression levels using flow cytometry showing that memory B-cells from 16 
tonsils, peripheral blood, and mesenteric lymph nodes were α5β1-positive in 95.1 ± 4.4 %, 83.6 ± 17 
3.1 %, and 54.01 ± 11.5 %, respectively. Notably, two distinct populations could be distinguished 18 
based on their α5β1 expression levels (Fig. 2D, 2G and 2J). Cells with high expression levels of 19 
α5β1 integrin were predominant in tonsils with only a minority of cells expressing low amounts 20 
of α5β1 (Fig. 2D and 2E). In contrast, in peripheral blood the majority of α5β1-positive memory 21 
B-cells expressed low integrin levels (Fig. 2G and 2H) and in mesenteric lymph nodes virtually 22 
all α5β1-positive memory B-cells showed low expression levels (Fig. 2J, 2K). Comparing the 23 
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frequencies of α5β1-posititve memory B-cells in the two complementary lymphoid tissues, tonsils 1 
and mesenteric lymph nodes, with the percentage of CD62L+ NALT-originating memory B-cells 2 
it is obvious that the α5β1-positive phenotype is restricted to memory B-cells selected in the 3 
NALT. Analysis of the mean fluorescence intensity (MFI) of α5β1 integrin on these cells revealed 4 
that α5β1high memory B-cells from tonsils and peripheral blood expressed 8- to 10-fold higher 5 
levels of α5β1 integrin than α5β1low memory B-cells (Fig. 2F, 2I), whereas no α5β1high cells were 6 
found in mesenteric lymph nodes (Fig. 2L). By contrast, virtually all naïve B-cells from tonsils, 7 
peripheral blood, and mesenteric lymph nodes invariably expressed amounts of α5β1 as high as 8 
the α5β1high tonsillar memory B-cells (Fig. 2G, H, I, M, N, O, S, T, U). Thus, tonsillar memory B-9 
cells differ from their counterparts from the other lymphatic tissues investigated by the virtue of 10 
their α5β1high expression, a characteristic common to the naïve B-cells from these tissues.  11 
 12 
Binding of EBV to α5β1-expressing memory B-cells. Next, we addressed the question, whether 13 
EBV uses α5β1 integrin to attach to NALT-originating memory B-cells as it does with epithelial 14 
cells. Two cellular receptors are important for EBV binding and entry into B-cells: CD21 and 15 
HLA class II (12, 28). Notably, both receptors are similarly expressed by memory B-cells from 16 
NALT and non-NALT (9). CD21 (CR2, C3R) which is a member of the complement receptor 17 
family acts as the main attachment factor for EBV on B-cells. Attachment of EBV to CD21 via 18 
the viral glycoprotein gp350/220 has been shown to induce receptor-mediated endocytosis. 19 
Within the endosomal compartment, a trimer of EBV glycoproteins consisting of gH, gL and 20 
gp42 binds to HLA class II. This interaction, in turn, triggers a pH-dependent membrane fusion 21 
of EBV with the endosomal membrane and allows nuclear transport of the capsid (12, 28). 22 
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First, we aimed at identifying whether the α5β1high memory B-cell subpopulation in tonsils 1 
is indeed more susceptible to EBV infection. Infection of tonsillar memory cells, unsorted or 2 
sorted by flow cytometry, showed a 20% - 30% higher infection frequency of α5β1high as 3 
compared to α5β1low memory B-cells (p = 0.05; Fig. 3A). FACS sorting was performed by gating 4 
on CD19+CD27+ cells followed by selection of α5β1 high and low expressing populations. 5 
Thereby, we could guarantee that the Ig isotype composition of the sorted cell populations 6 
reflected that of unsorted memory B-cells. This preferential infection susceptibility of α5β1high 7 
memory B-cells was also evident for memory B-cells from peripheral blood, where α5β1high 8 
memory B-cells exhibited a 30% higher infection frequency compared to their α5β1low 9 
counterparts (p = 0.025; Fig. 3B). Although the observed infection frequencies in the α5β1high 10 
memory B-cell compartment were only increased by 20% to 30% compared to the α5β1low 11 
memory B-cell compartment these differences might be sufficient in vivo and allow preferential 12 
infection of α5β1high memory B-cells. 13 
Next, to test whether EBV uses α5β1 integrin on NALT memory B-cells for attachment, 14 
we performed experiments using antibodies blocking EBV binding to α5β1 integrin or soluble 15 
recombinant β1 integrin to compete with EBV binding to cellular β1 integrin. As expected, 16 
blocking of CD21 or blocking of HLA class II molecules showed a significant reduction of EBV 17 
infection frequency legitimizing the use of spinoculation as a means to test EBV entry, as already 18 
shown in previous work (9) (Fig. 3C). Using antibodies to CD20 which is expressed by B-cells 19 
but is irrelevant for EBV infection, we found no changes in EBV infection frequencies compared 20 
to mock treatment. When using either anti-α5β1 blocking antibodies alone or in combination with 21 
anti-CD21 blocking antibodies, however, a dose-dependent reduction of the EBV infection 22 
frequency could be observed in tonsillar memory B-cells (Fig. 3C). As the combination of CD21 23 
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and α5β1 blocking antibodies showed a nearly complete inhibition of EBV entry it is unlikely that 1 
receptors other than CD21, HLA-DR and α5β1 integrin play a pivotal role in EBV entry into 2 
memory B-cells. Finally, recombinant soluble β1 integrin showed a similar dose-dependent 3 
inhibition of EBV infection of memory B-cells from tonsils in the presence of additional 4 
inhibition of the EBV glycoprotein gp350/220 (Fig. 3D). As positive controls, we also included 5 
blocking of gp350/220 alone or in combination with dilutions of anti-gp42 to block EBV 6 
penetration of the endosomal membrane. Thus, we could show by either blocking cellular α5β1 7 
integrin or by competing with recombinant β1 integrin that EBV indeed uses β1 integrin as factor 8 
to attach to memory B-cells. 9 
 10 
Lack of BMRF-2 impairs infection but not binding to B-cells. 11 
As α5β1 integrin has recently been shown to be critical for the infection of epithelial cells by 12 
EBV (34, 37-39) we chose to employ the described BMRF-2low EBV strain B27 to test whether 13 
the enhanced infection susceptibility of α5β1 integrin-expressing memory B-cells is due to 14 
BMRF-2-α5β1 integrin interactions. The BMRF-2low B27 and the B95.8EBfaV-GFP strains did 15 
not contain significant amounts of wild-type EBV (<2%; see materials and methods), therefore 16 
we can exclude any significant interference of wild-type EBV. EBV produced from both, 17 
B95.8EBfaV-GFP and B27 as well as wild-type B95.8 cells was used to infect B-cells isolated 18 
from tonsils. EBV infection was determined by flow cytometry for GFP fluorescence 24 h 19 
following inoculations of the cells. As expected, inoculation with wild type EBV showed no GFP 20 
fluorescence (Fig. 4A) and inoculation with B95.8EBfaV-GFP showed an increase of GFP 21 
fluorescence in around 50 % of the inoculated cells (Fig. 4B). In contrast, less than 5% GFP 22 
fluorescence was observed 24 hours after inoculation of the cells with BMRF-2low B27 EBV, 23 
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despite using the same amount of EBV DNA copies as measured by qPCR after DNAse 1 
treatment of the viral stocks preparation (Fig. 4C). 2 
Next, we compared the ability of B27 BMRF-2low and wilt-type EBV to bind to B-cells by 3 
performing binding experiments followed by quantification of bound EBV DNA copies by 4 
quantitative PCR to determine the number of EBV particles bound per cell. Both wild-type and 5 
BMRF-2low EBV were able to bind to B-cells with comparable, dose-dependent efficiency (Fig. 6 
4D). These results indicate that binding of EBV to B-cells is not influenced by BMRF-2-α5β1 7 
integrin interaction, and are in line with CD21 being the main receptor for EBV binding to B-8 
cells. To verify that, we performed binding experiments on monocytes which lack the expression 9 
of CD21. Binding to monocytes was impaired when using BMRF-2low EBV as compared to wild-10 
type EBV (Fig. 4E). Surprisingly, wild-type EBV binding to B-cells and monocytes was similar. 11 
This might indicate that additional binding sites for EBV may exist that partially compensate for 12 
the lack of CD21. 13 
Taken together, these data indicate that BMRF-2 is non-essential for the formation of 14 
enveloped EBV particles which are still able to bind to B-cells via CD21 and/or HLA-DR but 15 
exhibit reduced binding capacity to monocytes lacking expression of CD21. 16 
 17 
Role of integrin signaling for EBV entry into NALT memory B-cells. Even though the 18 
requirement of α5β1 integrin for EBV binding and infection of epithelial cells has been shown 19 
previously (38, 39), the participation of signaling events downstream of α5β1 integrin initiated 20 
through EBV binding and their contribution to EBV entry has not been elucidated. First evidence 21 
that α5β1 integrin may be involved in the EBV infection process of B-cells originating from the 22 
tonsil arises from our microarray analysis of tonsillar B-cells showing significant up-regulation of 23 
TIF6 and PTK2 (Fig. 3A), two genes downstream of α5β1 integrin. We therefore dissected the 24 
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integrin signaling pathway (11, 25) following EBV binding to memory B-cells. One of the initial 1 
steps in integrin signaling involves activation of focal adhesion kinase by phosphorylation of 2 
397Tyr followed by downstream signaling through PI3K p85α, c-Src kinases and cofilin to finally 3 
activate the depolymerization of the actin cytoskeleton (Fig. 5A) (11, 13, 22, 24, 40). To 4 
investigate whether EBV itself activates integrin signaling, thereby enhancing infection 5 
efficiency, we (i) followed the phosphorylation status of FAK, PI3K and cofilin over time upon 6 
binding of EBV to tonsillar memory B-cells treated or not with inhibitors of FAK, c-Src or PI3K 7 
p85α activation prior to infection with EBV and (ii) investigated the specificity of the BMRF-8 
2/integrin interaction by employing a recombinant EBV strain containing only trace amounts of 9 
BMRF-2 protein (38, 39). 10 
Binding of EBV tonsillar memory B-cells led to up-regulation of pFAK within 20 11 
minutes, followed by phosphorylation of c-Src, PI3K p85α, and cofilin (Fig. 5B). The kinetic of 12 
c-Src phosphorylation, which is much faster compared to that of PI3K p85α, indicates that c-Src 13 
actually phosphorylates PI3K p85α in the process of EBV entry. Furthermore, protrusions in the 14 
actin cytoskeleton similar to those observed upon activation of integrin signaling via fibronectin 15 
were readily detectable in memory B-cells when EBV binding took place (Fig. 5D). This was 16 
abolished when using heat-denatured EBV or heat-inactivated EBV, indicating that a 17 
conformationally-active BMRF-2 might be required for interaction with α5β1 integrin (Fig. 5D). 18 
We also conducted the experiments using a recombinant EBV containing only trace 19 
amount of BMRF-2 (38). Following challenge of memory B-cells with B27-BMRF-2low EBV, 20 
activation of FAK and all downstream effectors was abolished (Fig. 5C), as well as 21 
rearrangements of the actin cytoskeleton did not occur (Fig. 5D). Given that the B27-BMRF-2low 22 
EBV strain still contains residual BMRF-2 efficient activation of integrin signaling obviously 23 
requires a certain threshold amount of incorporated BMRF-2, that is present in wild-type but not 24 
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BMRF-2low EBV. Memory B-cells could not be infected with B27-BMRF-2low as determined by 1 
flow cytometry after staining for EBER (8) 48 hours after spinoculation, even if B27-BMRF-2low 2 
was used in up to 4-fold higher DNA concentration than wild-type EBV B95.8 (data not shown). 3 
These results indicate that interaction between EBV BMRF-2 and integrins on memory B-cells is 4 
crucial for the activation of the integrin signaling pathway. 5 
To further investigate the dependence of EBV entry into memory B-cells on integrin 6 
signaling, we used small-molecule phosphorylation inhibitors of FAK (AG-82), PI3K 7 
(Wortmannin and Ly-294002) or c-Src (PP2) prior to infection of memory B-cells by EBV-EGFP 8 
(Fig. 6A, B). These experiments showed that, indeed, the whole integrin signaling pathway is 9 
crucial for EBV entry as all used inhibitors significantly reduced the susceptibility of the cells to 10 
infection with EBV. Dependence on the actin cytoskeleton rearrangement was tested by pre-11 
treating the memory B-cells with Cytochalasin D which disrupts the actin microfilaments (23) 12 
showing increased EBV infection of memory B-cells (Fig. 6A, B). 13 
Taken together these results indicate that EBV binds to α5β1 integrin on NALT memory 14 
B-cells via its glycoprotein BMRF-2 and initiates activation of the integrin signal transduction 15 
pathway. Starting with the phosphorylation of FAK, c-Src, PI3K p85α and cofilin, this leads to 16 
depolymerization of the actin cytoskeleton and thus to a more efficient nuclear translocation of 17 
the EBV capsid. 18 
 19 
Induction of β1 integrin expression in memory B-cells isolated from non-NALT increases 20 
their susceptibility to EBV infection and transformation. As high expression of β1 integrin is 21 
linked to increased susceptibility to EBV infection of memory B-cells from NALT, we aimed at 22 
inducing β1 integrin expression in memory B-cells from non-NALT to investigate whether this 23 
would increase the susceptibility to EBV infection. Given that expression and activity of integrins 24 
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in B-cells is regulated mainly via B-cell-activating signals received by CD40 (18) or the B-cell 1 
receptor (27), we triggered memory B-cells, either from tonsils or peripheral blood, with CD40L 2 
plus anti-IgM antibody prior to EBV infection. Even though IgM-positive memory B-cells only 3 
make up a minority of tonsillar memory B-cells, stimulation with anti-IgM and CD40L has been 4 
shown to be sufficient for activation (36). The expression of β1 integrin was monitored by flow 5 
cytometry 18 hours post stimulation of cells. Whereas the percentage of memory B-cells 6 
expressing high levels of β1 integrin could not be increased by triggering tonsillar memory B-7 
cells (Fig. 7A), a three-fold increase was observed upon triggering of peripheral blood memory 8 
B-cells with CD40L plus anti-IgM (Fig. 7B, C). The susceptibility of memory B-cells from 9 
tonsils to EBV infection was not increased following in vitro triggering of these cells as 10 
demonstrated by spinoculation of B95.8EBfaV-GFP (Fig. 7D), but EBV infection of memory B-11 
cells from peripheral blood triggered with CD40L plus anti-IgM could be increased to 12 
percentages (60 %) matching those of their tonsillar counterparts (Fig. 7E). Thus, the proportion 13 
of memory B-cells from peripheral blood expressing high levels of β1 integrin as well as the 14 
susceptibility to EBV infection can substantially be increased in vitro. In contrast, tonsillar 15 
memory B-cells show already maximal percentages of cells expressing high levels of β1 integrin 16 
and susceptibility to EBV infection prior to in vitro triggering. 17 
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DISCUSSION 1 
In this work, we studied the mechanisms underlying the increased susceptibility to EBV infection 2 
of memory B-cells from tonsils as opposed to memory B-cells from other lymphoid sites. Our 3 
experimental data indicate that i) high expression of α5β1 integrin is unique to memory B-cells 4 
from the NALT, and EBV indeed uses β1 integrin as co-factor to attach to memory B-cells; ii) 5 
triggering the α5β1 integrin signaling pathway is a key event for EBV entry and thus for tonsillar 6 
B-cells’ susceptibility to in vitro infection; and iii) inducing expression of β1 integrin by 7 
activating memory B-cells with CD40L plus anti-IgM antibody increases the susceptibility of 8 
memory B-cells to EBV infection. We conclude that memory B-cells from tonsils exhibit 9 
increased susceptibility to EBV infection by virtue of their high basal activation status reflecting 10 
their high β1 integrin expression which mediates increased attachment and entry of the virus 11 
compared to memory B-cells from other lymphatic tissues where B-cell-activating factors or 12 
antigen are less abundant. 13 
The starting point of our hypothesis was the observation that tonsillar memory B-cells are 14 
particularly susceptible to ex vivo EBV infection (9) and that Janz et al. recently reported the 15 
possible existence of additional receptors for EBV on B-cells besides CD21 and HLA class II 16 
(14). Thus, we hypothesized that memory B-cells from the NALT exhibit specific properties 17 
rendering them highly susceptible for EBV infection, and we assumed that memory B-cells 18 
primed in the tonsils would keep their susceptibility to EBV infection when circulating in the 19 
blood. To address this hypothesis we employed the unique CD19+CD27+CD62L+ phenotype of 20 
NALT-originating memory B-cells (4, 5) to compare the relative infection susceptibilities of 21 
NALT-originating memory B-cells at distinct lymphoid compartments to that of memory B-cells 22 
selected at other lymphoid sites. Although NALT-originating (CD62L+) memory B-cells exhibit a 23 
higher susceptibility to EBV infection irrespective of whether they are isolated directly from 24 
 at Universitaet Zuerich on M
ay 3, 2010 
jvi.asm.org
D
ow
nloaded from
 
JVI02675-09 Version 2 
 21 
tonsils, peripheral blood, or mesenteric lymph nodes we excluded that CD62L itself functions as 1 
co-receptor for EBV by using neutralizing antibodies against CD62. We conclude that CD62L 2 
phenotypically marks a population of memory B-cells that have been selected in the NALT and 3 
have retained or obtained receptors required for an efficient infection with EBV. 4 
Recently, it has been found that the interaction of an EBV envelope protein, BMRF-2, 5 
with integrins α5β1 plays a role in the infection of polarized epithelial cells ((38) and Speck R, 6 
unpublished data) which do not express the known B-cellular receptors CD21 and HLA class II, 7 
both crucial for EBV entry. Here, we found that memory B-cells from the NALT express α5β1 8 
integrin at least at 10-fold higher levels as compared to their counterparts from peripheral blood 9 
or mesenteric lymph nodes. Notably, we identified two distinct populations, defined as α5β1high 10 
and α5β1low, and found most tonsillar memory B-cells expressing high amounts of α5β1 integrin 11 
and most peripheral blood or mesenteric lymph node memory B-cells expressing low amounts of 12 
α5β1 integrin. Given that blocking of and saturating α5β1 integrin by antibodies and the 13 
recombinant extracellular domain of β1 integrin, respectively, resulted in a clear decrease of EBV 14 
entry into memory B-cells, β1 integrin has a key role as co-factor in the viral entry process. 15 
Notably, memory B-cells from distinct lymphatic tissue express equal amounts of the cell surface 16 
molecules CD21 and HLA class II (9) which constitutes the EBV receptor complex: that 17 
consequently does not explain the distinct susceptibility to EBV infection. In contrast, the level of 18 
α5β1 integrin expression discriminates between degrees of susceptibility to EBV infection of 19 
memory B-cells. 20 
As we show, the susceptibility to EBV infection correlating to α5β1 integrin expression 21 
levels is mediated by binding of EBV’s structural protein BMRF-2 to α5β1 integrin. . Further, we 22 
show that each step of β1 integrin-mediated signaling leading to the activation of the downstream 23 
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targets (20) is crucial for EBV entry into B cells. Very importantly, activation of memory B-cells 1 
from peripheral blood with CD40L plus anti-IgM resulted in vigorous upregulation of β1 integrin 2 
expression. Thereby, the susceptibility of peripheral blood memory B-cells to infection by EBV, 3 
i.e. of memory B-cells which were not from the NALT was increased. Stimulation of the B-cell 4 
receptor results in increasing the expression levels of integrin, whereas CD40L, which binds to 5 
CD40 on B-cells and in addition to α5β1 integrin (18) may activate the down-stream integrin 6 
signaling pathway and in turn may lead to an increased uptake of EBV via actin cytoskeleton 7 
reorganizations. Thus, these data demonstrate clearly that the susceptibility of memory B-cells to 8 
EBV infection is greatly dependent on their activation status and the resulting high expression 9 
levels of β1 integrin. In fact, in a primary immune reaction, the CD40L expressed on activated T 10 
cells has a key role in subsequent activation of B-cells by binding to CD40 (35). Thus, the events 11 
described above may be operative during primary or secondary immune responses in the NALT 12 
explaining its marked susceptibility to EBV infection and its central role in EBV pathogenesis. 13 
Whether the interaction of EBV’s essential envelope protein gH with integrins  αVβ6 or  αvβ8, 14 
which very recently have been shown to trigger epithelial cell fusion by EBV (7), plays a role for 15 
B-cell infection remains to be investigated.  16 
We propose a model in which EBV takes advantage of targeting activated CD62L+α5β1high 17 
memory B-cells which preferentially reside in or home to NALT and, following circulation, are 18 
likely to home back to NALT. We have previously shown that naïve B-cells from distinct tissues 19 
are equally highly susceptible to EBV infection ex vivo (9). Here, we report that naïve B-cells 20 
from distinct tissues essentially express α5β1high, contrasting memory B-cells expressing α5β1high 21 
preferentially when originating from NALT. Our data speak in favor of a direct infection of 22 
tonsillar memory B-cells with EBV which, in addition to primary infection of naïve (33) and 23 
germinal center B-cells (2, 19), contributes to a more efficient establishment of EBV persistence. 24 
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In NALT, the memory B-cells may encounter recall antigen and subsequently either propagate 1 
EBV as latent infection to progeny cells or undergo differentiation to plasma cells resulting in 2 
lytic replication of EBV which then can be transmitted via saliva to new susceptible hosts. 3 
Triggering of CD40 and the B-cell receptor mediated by exposure to microorganisms may be 4 
involved in this process, as such triggering increased the proportion of cells expressing high 5 
levels of β1 integrin. NALT is readily accessible to a wide variety of antigen explaining why 6 
memory B-cells generated within and homing back to the NALT are much more readily found in 7 
an activated, i.e. β1 integrin high expressing state compared to remote lymphoid organs which are 8 
not accessible by antigen or pathogens directly but only following initial immune recognition by 9 
sentinel immune cells such as dendritic cells. The idea that EBV establishes persistence by direct 10 
infection of memory B-cells has also been proposed by Kurth et al. who examined EBV-infected 11 
B-cells in infectious mononucleosis (15, 16). Our findings give a detailed insight of EBV B-cell 12 
infection and biology. 13 
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FIGURE LEGENDS 1 
FIG. 1. EBV preferentially infects memory B-cells expressing CD62L. (A) EBV infection of 2 
memory B-cells from tonsils, peripheral blood and mesenteric lymph nodes, respectively. EBV 3 
infection was performed by spinoculation of B95.8EBfaV-GFP supernatants. Results shown are 4 
percentages of EGFP+ cells gated for CD19+CD27+ memory B-cells. (B) Percentage of memory 5 
B-cells (CD19+CD27+) from tonsils, peripheral blood and mesenteric lymph nodes expressing 6 
CD62L (C) EBV infection of CD62L+ and CD62L- memory B-cells from tonsils, peripheral 7 
blood (PB) and mesenteric lymph nodes (LN), respectively. (D) EBV infection frequency 8 
susceptibility of tonsillar memory B-cells following blocking of CD62L using blocking 9 
antibodies. Data are percentages of EGFP+ cells gated for CD19+CD27+ cells. Results shown are 10 
mean ± SD from 3-8 replicates. P values were calculated by using the Mann-Whitney t-test. * p = 11 
0.05, ** p = 0.03, *** p = 0.02, **** p = 0.01, ***** p = 0.002. 12 
 13 
FIG. 2. α5β1 integrin is preferentially expressed on memory B-cells from NALT. (A) Gene 14 
expression profiling of integrin-related genes comparing tonsillar and peripheral blood B-cells. 15 
Scale indicates fold regulation. (B) Immunofluorescence of α5β1 integrin on memory B-cells 16 
from tonsil and (C) peripheral blood (PB). Bar, 50 µm (D - U) Quantification of α5β1 integrin 17 
expression on (D-F, J-L, P-R) memory B-cells and (G-I, M-O, S-U) naïve B-cells by flow 18 
cytometry. Data shown are percentages of α5β1-positive memory and naïve B-cells from (D-E, 19 
G-H) tonsils, (J-K, M-N) peripheral blood and (P-Q, S-T) lymph nodes and relative fluorescence 20 
intensity of β1 integrin on memory and naïve B-cells from tonsils (F, I), peripheral blood (L, O), 21 
and mesenteric lymph nodes (R, U), respectively. Data shown are mean ± SD from 3-4 biological 22 
replicates. *, not detected. P values were calculated by using the Mann-Whitney t-test. ** p = 23 
0.03. 24 
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 1 
FIG. 3. Integrin α5β1 is required for efficient attachment and entry of EBV on memory B-cells. 2 
(A) Infection frequency of α5β1low and α5β1high CD19+CD27+ memory B-cells either by 3 
inoculation of pooled tonsillar memory B-cells or fluorescence-activation cell-sorted memory B-4 
cell populations with B95.8EBfaV-GFP by spinoculation. (B) Infection frequency of α5β1low and 5 
α5β1
lhigh CD19+CD27+ memory B by inoculation of pooled peripheral blood memory B-cells with 6 
B95.8EBfaV-GFP by spinoculation. (C) Inhibition of cellular receptors required for EBV 7 
infection (CD21 and HLA class II), α5β1 integrin as well as non-relevant surface proteins (CD20) 8 
on memory B-cells from tonsils using different concentrations of blocking antibodies and 9 
combinations. (D) Inhibition of the viral glycoproteins gp350/220 and gp42 in combination with 10 
competition inhibition of recombinant soluble β1 integrin using tonsillar memory B-cells. Data 11 
shown in (A) and (B) are mean ± SD from 3 biological replicates. P values were calculated using 12 
the Mann-Whitney t-test. Data shown in (C) and (D) are from one representative experiment out 13 
of three. * p = 0.05, ** p = 0.025. 14 
 15 
FIG. 4. Lack of BMRF-2 impairs infection but not binding to B-cells. (A-C) Flow cytometry to 16 
detect GFP fluorescence 24 h after spinoculation of isolated tonsillar B-cells with either (A) wild-17 
type B95.8, (B) B95.8EBfaV-GFP or (C) B27 BMRF-2low EBV. The viral stocks used for 18 
spinoculation were normalized to 2 x 108 EBV DNA copies /ml after DNAse treatment. Shown is 19 
one of three representative experiments. (D-E) Binding efficiency of wild-type and B27 BMRF-20 
2low EBV to either (D) B-cells or (E) CD14+ monocytes as determined by quantitative PCR 21 
detecting EBV DNA copies bound per cell. Data shown are mean ± SD of three independent 22 
experiments. moi, multiplicity of infection. 23 
 24 
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FIG. 5. EBV binding to integrin via BMRF-2 initiates signaling mandatory for virus entry into 1 
memory B-cells. (A) Proposed signal transduction cascade initiated by EBV BMRF-2 binding to 2 
α5β1 integrin. Following binding of BMRF-2 to cellular α5β1 integrin, a rapid phosphorylation of 3 
FAK initiates signal transduction via phosphorylation of the downstream mediators c-Src, p85α 4 
and cofilin and in between activation of the regulatory small GTPase RhoA, analogous to that 5 
initiated by binding of fibronectin to α5β1 integrin (20). The resulting actin reorganization then 6 
facilitates EBV entry. (B, C) Phosphorylation (p-) of FAK, c-Src, p85α, and cofilin, following 7 
binding of (B) B95.8 wild-type or (C) B27-BMRF-2low EBV to isolated tonsillar memory B-8 
cells. (D) Initiation of actin filament reorganization (upper panel) triggered by binding of EBV, 9 
Fibronectin, heat-denatured EBV, heat-inactivated (h.i.) EBV, or B27-BMRF-2low EBV to 10 
isolated tonsillar memory B-cells. Actin was stained using FITC-Phalloidin. Cells were 11 
additionally stained with DAPI (4,6 diamidino-2-phenylindole) to visualize nuclei (lower panel, 12 
merge). Bar, 20µm. 13 
 14 
FIG. 6. Activation of the integrin signal transduction pathway is crucial for EBV entry into 15 
memory B-cells. (A, B) Inhibition of signaling molecules c-Src, PI3 kinase, FAK, activated 16 
downstream of integrin impact the susceptibility of tonsillar memory B-cells to EBV infection 17 
using B95.8EBfaV-GFP viral supernatants. Inhibitors used were AG-82 (FAK), PP2 (c-Src), 18 
Wortmannin and Ly-294002 (PI3K). Cytochalasin D was included to show the dependence of 19 
infection susceptibility of memory B-cells on actin cytoskeleton depolymerization. Cells were 20 
counterstained for CD19 and CD27 to identify memory B-cells and determine their infection 21 
frequency by flow cytometry. Results shown are from one representative experiment out of two 22 
experiments. 23 
 24 
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FIG. 7. Augmenting β1 integrin expression on memory B-cells increases their susceptibility to 1 
EBV infection and transformation. (A-C) Expression of β1 integrin on memory B-cells isolated 2 
from (A) tonsils or (B, C) peripheral blood without or following 18 h treatment with CD40L plus 3 
anti-IgM. (D, E) Infection susceptibility to EBV of memory B-cells from (D) tonsils or (E) 4 
peripheral blood treated for 18 h as described above as determined by flow cytometry 24 h 5 
following inoculation of memory B-cells by B95.8EBfaV-GFP by spinoculation.  6 
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Figure 2 1 
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